探讨吉西他滨/白蛋白结合型紫杉醇（AG方案）联合安罗替尼和PD-1抑制剂一线治疗晚期胰腺癌（PC）的临床疗效和不良反应。 52例晚期PC患者的治疗数据对2019年8月至2023年3月徐州医科大学附属医院（中国徐州）的住院病例进行回顾性分析。根据治疗方案将患者分为两组，其中化疗组（AG方案）27例患者，联合治疗组（AG方案联合安罗替尼和PD-1抑制剂）25例患者。比较两组患者的总生存期（OS）、无进展生存期（PFS）、客观缓解率（ORR）、疾病控制率（DCR）及不良反应情况。采用Kaplan-Meier法绘制两组生存曲线，并通过log-rank检验比较两组间PFS和OS的差异。通过单变量和多变量 Cox 回归分析来确定影响预后的独立危险因素。联合治疗组的中位 OS 和 PFS 显着长于化疗组（OS，12.8 个月 vs. 7.9 个月，P = 0.005；PFS， 5.6 个月与 4.4 个月，P = 0.003）。两组之间的 ORR 无显着性差异（32.0% vs. 25.9%，P=0.629），联合治疗组的 DCR 明显优于化疗组（84.0% vs. 59.3%，P=0.629）。 0.049）。两组均以1~2级不良反应为主，无不良反应相关死亡发生。与单纯化疗相比，AG方案联合安罗替尼和PD-1抑制剂一线治疗晚期晚期患者显示出更高的疗效。 PC，不良反应也是可控的。版权所有©2024。Elsevier B.V.出版。

To investigate the clinical efficacy and adverse reactions of gemcitabine/nab-paclitaxel (AG regimen) combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer (PC).Data of 52 patients with advanced PC who were treated in the Affiliated Hospital of Xuzhou Medical University (Xuzhou, China) between August 2019 and March 2023 were retrospectively analyzed. According to the treatment regimen, patients were divided into two groups, including 27 patients in the chemotherapy group (AG regimen) and 25 patients in the combined treatment group (AG regimen combined with anlotinib and PD-1 inhibitors). Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse reactions were compared between the two groups. The survival curves of the two groups were drawn using the Kaplan-Meier method, and the differences in PFS and OS between the two groups were compared by the log-rank test. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors influencing prognosis.The median OS and PFS in the combined treatment group were significantly longer than those in the chemotherapy group (OS, 12.8 vs. 7.9 months, P = 0.005; PFS, 5.6 vs. 4.4 months, P = 0.003). There was no significant difference in ORR between the two groups (32.0 % vs. 25.9 %, P = 0.629), and DCR in the combined treatment group was significantly better than that in the chemotherapy group (84.0 % vs. 59.3 %, P = 0.049). Grade 1-2 adverse reactions were predominant in both groups, and no adverse reaction-related deaths occurred.Compared with chemotherapy alone, AG regimen combined with anlotinib and PD-1 inhibitors exhibited to have a higher efficacy for the first-line treatment of advanced PC, and the adverse reactions were also controllable.Copyright © 2024. Published by Elsevier B.V.